Montelucaste Teva (Montelukast Sodium)

Montelukast sodium selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. By preventing leukotrienes D4, E4 and related mediators from binding, it reduces bronchoconstriction, mucus production, vascular leakage, and eosinophilic inflammation that underlie asthma and allergic airway disease.

The specific dose of Montelucaste Teva is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and therapeutic goals. Healthcare professionals follow approved labeling and clinical guidelines to select an appropriate regimen for each individual.

Safety data for montelukast in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit outweighs any possible risk. Limited information is available for lactation; therefore, a prescriber should evaluate the risk‑benefit ratio before recommending use while breastfeeding.

To request Montelucaste Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and necessary import documentation.

Montelucaste Teva belongs to the leukotriene receptor antagonist class, offering an oral, once‑daily option that targets leukotriene‑mediated inflammation. Unlike inhaled corticosteroids or long‑acting β2‑agonists, it does not provide immediate bronchodilation but is useful as an add‑on or maintenance therapy, especially for patients with aspirin‑exacerbated respiratory disease or those preferring oral medication.

Montelucaste Teva should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Montelucaste Teva is taken orally, usually as a whole tablet with or without food. The exact timing (e.g., morning or evening) and frequency are set by the prescriber based on the patient’s therapeutic plan and any concomitant medications.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, hepatotoxicity indicated by elevated liver enzymes, and neuropsychiatric effects such as depression, agitation or suicidal thoughts. Patients should be instructed to seek immediate medical attention if any of these symptoms develop.

Montelucaste Teva is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s inactive ingredients. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in those who have experienced serious allergic reactions to other leukotriene‑modifying agents.